Excellamol is advancing five OncoPDC programs targeting hard-to-treat, high-mortality cancers, including glioblastoma (GBM), pediatric diffuse midline glioma, and pancreatic ductal adenocarcinoma. Through two FDA INTERACT meetings, Excellamol has achieved key regulatory alignment, significantly de-risking the development pathway toward IND submission and a planned first-in-human trial of its lead GBM candidate in 2028.